Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIDO-361 in spinal and bulbar muscular atrophy
2023-507128-22-00Phase 2Completed
- Sponsor
- Nido Biosciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in spinal and bulbar muscular atrophy (SBMA) comparing NIDO-361 with Placebo (2 arms). Primary endpoints: Change from baseline in thigh and total lean muscle volume, Adverse events and serious adverse events and 2 more. Started Jan 2024; status: completed.
02
Drugs
nido-361
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on 2023-507128-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507128-22-00.